SRT Stock Chart & Stats
CHF187.62
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF187.62
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF158.56 - CHF189.81
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
CHF13.86B
Enterprise ValueCHF17.90K
Total Cash (Recent Filing)CHF306.90M
Total Debt (Recent Filing)CHF4.05B
Price to Earnings (P/E)83.7
Beta0.49
Next Earnings
Oct 22, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.83
Shares OutstandingN/A
10 Day Avg. Volume2
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.97
Revenue Forecast (FY)CHF3.49B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthStrong consumables growth supports recurring revenue because customers repeatedly purchase single-use components and filtration products for each production run. Sartorius also reported double-digit consumables CAGR since 2019, indicating durable adoption and customer integration.
Bioprocess Growth And Margin StrengthBioprocess Solutions combines attractive growth with a high and improving margin, reinforcing its role as the core earnings engine. Customer reliance on regulated manufacturing workflows can support durable demand as biologics production expands.
Improving Cash GenerationHigher operating and free cash flow improves Sartorius’s ability to fund innovation, service debt and invest in capacity. The accompanying reduction in leverage and higher equity ratio strengthen financial resilience, even though indebtedness remains meaningful.
Bears Say
Elevated Leverage And Moderate ReturnsThe substantial debt burden limits flexibility if biopharma demand weakens or investments require additional funding. Moderate returns indicate that profitability has not yet fully caught up with the enlarged capital base, making deleveraging an ongoing priority.
Low Net Margin And Uneven Cash ConversionAlthough EBIT margins improved, limited bottom-line conversion suggests financing, tax or other costs continue to dilute operating gains. Uneven cash conversion can constrain debt reduction and make earnings quality less consistent through the cycle.
Customer Order Timing And External HeadwindsDelayed cell- and gene-therapy orders may shift revenue into late 2026 or 2027, reducing visibility for near-term growth and recurring sales. Tariff and currency effects add further uncertainty, particularly in the Americas and reported results.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was CHF158.56 and its highest was CHF189.81 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is CHF13.86B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Oct 22, 2026 which is in 42 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Jul 23, 2026. The company reported CHF1.208 earnings per share for the quarter, missing the consensus estimate of CHF1.233 by -CHF0.025.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG does not currently pay dividends.
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.17.
How many shares outstanding does Sartorius AG have?
Currently, no data Available
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of CHF1.208 in its last earnings report, missing expectations of CHF1.233. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in CH:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―